Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$261.28MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey Dayno
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 293
- Beta
- 0.93
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 5.77
Financials
Revenue
$261.28M+4258.3%Net Income
$75.43MEBITDA
$102.30MFree Cash Flow
$92.43MEPS (diluted)
$1.28Shares Outstanding (diluted)
58.77M+6.3%Operating Expenses
$108.77MCash & Debt
$667.79MReturn of Capital
$1.07MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $868.45M | $158.69M | $2.76 |
| 2024 | $714.73M | $145.49M | $2.56 |
| 2023 | $582.02M | $128.85M | $2.17 |
| 2022 | $437.86M | $181.47M | $3.07 |
| 2021 | $305.44M | $34.60M | $0.60 |
| 2020 | $159.74M | $-36.94M | $-1.12 |
| 2019 | $6.00M | $-151.98M | $-2.94 |
| 2018 | $0.00 | $-39.90M | $-1.42 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $4.06
- Implied price
- $56.78
- Return from $39.64
- 7.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $28.23 — -28.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -2.0% | -8.8% | -5.5% | -2.5% | 0.1% | 2.5% |
| 3.0% | -4.2% | -0.6% | 2.5% | 5.2% | 7.8% |
| 8.0% | 0.5% | 4.2% | 7.5% | 10.4% | 13.0% |
| 13.0% | 5.1% | 9.0% | 12.4% | 15.5% | 18.2% |
| 18.0% | 9.8% | 13.8% | 17.4% | 20.6% | 23.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5d ago·Positive
…nounces Poster Presentation at the 17th European Narcolepsy Days PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.
View source ↗ - Newsglobenewswire.com·33d ago·Positive
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece.
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $1.11 per share
Typical surprise -5.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$1.28 vs $0.96beat
- Thu, May 7$0.55 vs $0.76miss
- Tue, Feb 24$0.38 vs $0.84miss
- Tue, Nov 4$0.87 vs $0.92miss
- Tue, Aug 5$0.68 vs $0.78miss
- Tue, May 6$0.78 vs $0.59beat
Estimates and results for HRMY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HRMY officers and directors.
- Bought
- —
- Sold
- $5.9m
0 trades
13 trades
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Budur Kumarsold
- Kapadia Sandipsold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HRMY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.